- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06592833
Psilocybine werkingsmechanisme (MOA)
Onderzoek naar de rol van serotonine in het werkingsmechanisme van psilocybine bij patiënten met een depressieve stoornis
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
In this study, the researchers want to probe the role of the 5-HT2A receptor in mediating the subjective effects of psilocybin. While previous studies have shown that blockage of the 5-HT2A receptor reduces the psychedelic experience in humans, an animal study revealed that blockage of the 5- HT2A receptor abolished the psychedelic effects without affecting the antidepressant response. This suggests that the pathway responsible for the antidepressant response is dissociated from the psychedelic experience pathway, which is mediated by 5-HT2A signaling.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Depression and Anxiety Center Icahn School of Medicine at Mount Sinai
- Telefoonnummer: (212) 241-6539
- E-mail: dac@mssm.edu
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10025
- Werving
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research
-
Hoofdonderzoeker:
- James Murrough
-
Contact:
- Depression and Anxiety Center
- Telefoonnummer: (212) 241-6539
- E-mail: dac@mssm.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 21-80 years, any gender
- Current primary diagnosis of Unipolar Major Depressive Disorder (MDD) without psychotic features using DSM-5 criteria
- 24-item Hamilton Rating Scale for Depression (HRSD) ≥16
- Current diagnosis of Major Depressive Episode (MDE)
- Capable of providing informed consent and complying with study procedures
- Currently using or agreeing to use a highly effective contraception, if person of childbearing potential (such as condoms, IUD, or oral contraceptive), for duration of the study. Male participants agree to use highly effective contraception with partners of childbearing potential
- Discontinuation of any serotonergic drug for at least 2 weeks or 5 half-lives (whichever of the two is longer) prior to psilocybin exposure
Exclusion Criteria:
- Any severity of substance use disorder in the last 6 months (excluding tobacco use disorder) as determined by DSM-V criteria via the SCID
- Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months
- Use of psychedelics in the last 12 months
- Non-medical or illicit use of ketamine in the past 12 months
- Negative reaction after prior use of psychedelics
- Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder
- Severe depression as indicated by Clinical Global Impressions (CGI)-Severity score ≥ 5 at baseline
- Significant suicidal ideation as indicated by C-SSRS > 2 in the past 6 months at time of screening
- Suicide attempt in the past 2 years, or clinician concern that the patient poses a risk to self or others
- Acute, severe, or unstable medical illness
- Weight > 300 lbs., or girth size incompatible with scanner bore
- Any conditions/qualities that make participation in MRI imaging unsafe*
- Any physical or intellectual disability adversely affecting ability to complete assessments.
- Current pregnancy or currently breast feeding.
- Any clinically significant abnormal lab test result, including clinically significant abnormal baseline liver and/or renal function tests
- Currently being treated with a contraindicated medication. Contraindicated medications include antipsychotic medications, serotonergic antidepressant medications, and mood stabilizers that may attenuate the effects of psilocybin. Strong CYP3A4 inhibitors and inducers are also contraindicated. UGT1A9 and UGT1A10 inhibitors, monoamine oxidase, and aldehyde or alcohol dehydrogenase inhibitors are prohibited concomitant medications.
- History of abnormal QT prolongation or QTc interval >450 ms on screening
- Use of medications known to prolong the QT interval
- Any congenital prolongation of the QT interval or a family history of long QT syndrome
- A family history of sudden cardiac or unexplained death
- A family history in a first-degree relative of psychosis/schizophrenia or related disorders
- A first-degree family history of bipolar disorder
- A history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication
- A history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/torsades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome)
- Preexisting cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension, hypertension, tachycardia, and any cardiovascular conditions that may be worsened/exacerbated by elevated blood pressure or heart rate.
- Baseline vital sign parameters at screening and on day of dosing prior to dose that exceed to the following values for systolic blood pressure (SBP), diastolic (DBP), and heart rate (HR): SBP > 139 mmHg, DBP 89 mmHg, and HR > 90 bpm
- Hypersensitivity to either psilocybin or pimavanserin
- Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin
- Positive urine toxicology at screening
- Any clinically significant abnormalities on 12-lead electrocardiogram (ECG)
- Mini-Mental State Examination (MMSE) score < 25
- Brief Psychiatric Rating Scale (BPRS-6) > 5
- Potential fall risk
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Psilocybin + Pimavanserin
single dose Psilocybin and single dose Pimavanserin |
Psilocybin, 25mg, given once orally. Pimavanserin, 34mg, given once orally
Andere namen:
|
|
Placebo-vergelijker: Psilocybin + Placebo
single dose Psilocybin and single dose Placebo |
Psilocybin, 25mg, given once orally. Matching placebo. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mystical Experience Questionnaire (MEQ-30) Score
Tijdsspanne: 6 hours post-treatment
|
Acute subjective effects of psilocybin measured by the Mystical Experience Questionnaire (MEQ-30). Full Scale ranges from 0 to 150, with higher scores indicating more mystical experience. |
6 hours post-treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Montgomery-Åsberg Depression Rating Scale (MADRS) Score
Tijdsspanne: 7 days after dosing
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) will be used to measure improvement in depressive symptoms 7 days after dosing. This 10-item clinician-rated scale measures the severity of depressive symptoms. Full scale ranges from 0 to 60, with higher scores indicating more depressive symptoms. |
7 days after dosing
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: James Murrough, Icahn School of Medicine at Mount Sinai
- Hoofdonderzoeker: Rachel Fremont, Icahn School of Medicine at Mount Sinai
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Stemmingsstoornissen
- Depressieve stoornis
- Depressieve stoornis, majoor
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Alkaloïden
- Indolen
- Indol alkaloïden
- Indolizidines
- Indolizines
- Tryptamines
- Psilocybine
- Pimavanserin
Andere studie-ID-nummers
- STUDY-23-00855
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Because this study is privately funded, the research team is not required to share IPD.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .